Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sustiva efavirenz: Marketed

DuPont published in The New England Journal of Medicine previously reported 48-week results from 450 patients in an

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE